LPAA
Launch One Acquisition Corp.10.59
+0.03+0.28%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
304.46MP/E (TTM)
35.30Basic EPS (TTM)
0.30Dividend Yield
0%Recent Filings
8-K
SPAC deal terminated
Launch One Acquisition Corp. mutually terminated its Business Combination Agreement with Minovia Therapeutics and related parties on January 30, 2026, ending the proposed SPAC merger. All ancillary agreements terminated automatically, with full mutual releases from liabilities. No costs disclosed. The SPAC now hunts fresh targets.
10-Q
Q3 FY2025 results
Launch One's Trust Account grew to $243.1M at September 30, 2025, up from $235.5M year-end 2024, fueled by $2.6M quarterly interest income that outpaced $517K operating expenses for $0.07 diluted EPS. Nine-month net income hit $6.2M or $0.22/share on $7.6M Trust interest, while cash outside Trust dipped to $98K amid a $332K working capital deficit. Signed Minovia merger June 2025 (amended August), eyeing $180M consideration plus $57.5M earnout tied to share price or FDA milestones; Bridge Financing of $5M at $120M pre-money valuation due within 60 days. No debt beyond $11M deferred underwriting fee. Trust yields impress. Yet Nasdaq delisting looms if no deal by July 2026.
10-Q
Q2 FY2025 results
Launch One Acquisition Corp. posted a net income of $1.9M for Q2 FY2025 ended June 30, 2025, swinging from a $22K loss a year earlier, thanks to $2.5M in interest from its Trust Account—now at $240.5M after accretion—while general and administrative costs climbed to $638K from formation expenses. Six-month net income hit $4.2M, with EPS at $0.15 for both redeemable Class A and non-redeemable Class B shares, reconciling neatly to 23M and 5.75M diluted shares outstanding. Cash outside the Trust dipped to $264K amid $587K used in operations, but no debt burdens the balance sheet. The SPAC inked a business combination with Minovia Therapeutics on June 25, 2025, for $180M in Pubco shares plus earnouts, amended August 12 to extend bridge financing timelines. Solid Trust growth offsets rising costs. Yet regulatory hurdles in Israel could snag the deal.
8-K
Launch One SPAC merges with Minovia
Launch One Acquisition Corp. signed a business combination agreement on June 25, 2025, to merge with Minovia Therapeutics Ltd., forming Mito US One Ltd. as the public entity listed on Nasdaq. Minovia shareholders will receive $180 million in Pubco shares at the redemption price, plus potential $57.5 million earnout shares over five years tied to stock price or FDA milestones for Pearson syndrome. The deal requires $23 million minimum cash post-redemptions and financing, yet hinges on approvals amid IP and regulatory risks.
8-K
SPAC merger with Minovia announced
Launch One Acquisition Corp. signed a business combination agreement with Minovia Therapeutics on June 25, 2025, valuing Minovia at $180 million pre-money, plus at least $5 million bridge financing and $18 million PIPE, with $57.5 million earnout potential. The deal merges Minovia's mitochondrial augmentation technology—showing safety in 23 patients and FDA Fast Track for Pearson Syndrome—into a Nasdaq-listed entity, expected to close Q4 2025, funding pivotal trials and longevity offerings. Redemptions could trim Launch One's $239.7 million trust cash. Yet risks loom if approvals falter.
IPO
Sector
Industry
AAM
AA Mission Acquisition Corp.
10.65+0.03
BAYA
Bayview Acquisition Corp
11.63-0.01
BSAA
BEST SPAC I Acquisition Corp.
10.10+0.00
LCCC
Lakeshore Acquisition III Corp.
10.21+0.00
LOKV
Live Oak Acquisition Corp. V
10.27+0.02
LPBB
Launch Two Acquisition Corp.
10.46-0.01
PACH
Pioneer Acquisition I Corp
10.11+0.01
SIMA
SIM Acquisition Corp. I
10.57+0.01
SPKL
Spark I Acquisition Corp.
11.23+0.08
WLAC
Willow Lane Acquisition Corp.
11.86+0.45